版本:
中国

BRIEF-Alnylam Pharmaceuticals expects to end 2017 with over $1 bln in cash, cash equivalents, fixed income marketable securities

June 6 Alnylam Pharmaceuticals Inc

* Company updated its cash guidance for year ending december 31, 2017 - sec filing

* Alnylam Pharmaceuticals-now expects to end 2017 with over $1.0 billion in cash, cash equivalents, fixed income marketable securities, restricted investments Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐